181 related articles for article (PubMed ID: 16002461)
21. Development of bisubstrate analog inhibitors of aspartate N-acetyltransferase, a critical brain enzyme.
Mutthamsetty V; Dahal GP; Wang Q; Viola RE
Chem Biol Drug Des; 2020 Jan; 95(1):48-57. PubMed ID: 31260162
[TBL] [Abstract][Full Text] [Related]
22. Acetate supplementation induces growth arrest of NG2/PDGFRα-positive oligodendroglioma-derived tumor-initiating cells.
Long PM; Tighe SW; Driscoll HE; Moffett JR; Namboodiri AM; Viapiano MS; Lawler SE; Jaworski DM
PLoS One; 2013; 8(11):e80714. PubMed ID: 24278309
[TBL] [Abstract][Full Text] [Related]
23. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.
Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B
Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223
[TBL] [Abstract][Full Text] [Related]
24. Brain N-acetylaspartate as a molecular water pump and its role in the etiology of Canavan disease: a mechanistic explanation.
Baslow MH
J Mol Neurosci; 2003; 21(3):185-90. PubMed ID: 14645985
[TBL] [Abstract][Full Text] [Related]
25. Renewal of oligodendrocyte lineage reverses dysmyelination and CNS neurodegeneration through corrected N-acetylaspartate metabolism.
Lotun A; Li D; Xu H; Su Q; Tuncer S; Sanmiguel J; Mooney M; Baer CE; Ulbrich R; Eyles SJ; Strittmatter L; Hayward LJ; Gessler DJ; Gao G
Prog Neurobiol; 2023 Jul; 226():102460. PubMed ID: 37149081
[TBL] [Abstract][Full Text] [Related]
26. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
Baslow MH; Guilfoyle DN
Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678
[TBL] [Abstract][Full Text] [Related]
27. Intraneuronal N-acetylaspartate supplies acetyl groups for myelin lipid synthesis: evidence for myelin-associated aspartoacylase.
Chakraborty G; Mekala P; Yahya D; Wu G; Ledeen RW
J Neurochem; 2001 Aug; 78(4):736-45. PubMed ID: 11520894
[TBL] [Abstract][Full Text] [Related]
28. Lithium citrate for Canavan disease.
Janson CG; Assadi M; Francis J; Bilaniuk L; Shera D; Leone P
Pediatr Neurol; 2005 Oct; 33(4):235-43. PubMed ID: 16194720
[TBL] [Abstract][Full Text] [Related]
29. Glyceryl triacetate feeding in mice increases plasma acetate levels but has no anticonvulsant effects in acute electrical seizure models.
Xu W; Neal ES; Plan M; Borges K
Epilepsy Behav; 2022 Dec; 137(Pt A):108964. PubMed ID: 36343532
[TBL] [Abstract][Full Text] [Related]
30. Canavan's spongiform leukodystrophy: a clinical anatomy of a genetic metabolic CNS disease.
Baslow MH
J Mol Neurosci; 2000 Oct; 15(2):61-9. PubMed ID: 11220786
[TBL] [Abstract][Full Text] [Related]
31. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
[TBL] [Abstract][Full Text] [Related]
32. Pathological Bergmann glia alterations and disrupted calcium dynamics in ataxic Canavan disease mice.
Hull VL; Wang Y; Burns T; Sternbach S; Gong S; McDonough J; Guo F; Borodinsky LN; Pleasure D
Glia; 2023 Dec; 71(12):2832-2849. PubMed ID: 37610133
[TBL] [Abstract][Full Text] [Related]
33. The pathogenesis of, and pharmacological treatment for, Canavan disease.
Wei H; Moffett JR; Amanat M; Fatemi A; Tsukamoto T; Namboodiri AM; Slusher BS
Drug Discov Today; 2022 Sep; 27(9):2467-2483. PubMed ID: 35636725
[TBL] [Abstract][Full Text] [Related]
34. Relationship between enzyme properties and disease progression in Canavan disease.
Zano S; Wijayasinghe YS; Malik R; Smith J; Viola RE
J Inherit Metab Dis; 2013 Jan; 36(1):1-6. PubMed ID: 22850825
[TBL] [Abstract][Full Text] [Related]
35. High Throughput Screening Cascade To Identify Human Aspartate
Nešuta O; Thomas AG; Alt J; Hin N; Neužilová A; Long S; Tsukamoto T; Rojas C; Wei H; Slusher BS
ACS Chem Neurosci; 2021 Sep; 12(18):3445-3455. PubMed ID: 34477360
[TBL] [Abstract][Full Text] [Related]
36. Canavan disease: a white matter disorder.
Kumar S; Mattan NS; de Vellis J
Ment Retard Dev Disabil Res Rev; 2006; 12(2):157-65. PubMed ID: 16807907
[TBL] [Abstract][Full Text] [Related]
37. Acetate supplementation modulates brain adenosine metabolizing enzymes and adenosine A₂A receptor levels in rats subjected to neuroinflammation.
Smith MD; Bhatt DP; Geiger JD; Rosenberger TA
J Neuroinflammation; 2014 Jun; 11():99. PubMed ID: 24898794
[TBL] [Abstract][Full Text] [Related]
38. Metabolic acetate therapy for the treatment of traumatic brain injury.
Arun P; Ariyannur PS; Moffett JR; Xing G; Hamilton K; Grunberg NE; Ives JA; Namboodiri AM
J Neurotrauma; 2010 Jan; 27(1):293-8. PubMed ID: 19803785
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease.
Surendran S
Med Hypotheses; 2010 Dec; 75(6):533-4. PubMed ID: 20673702
[TBL] [Abstract][Full Text] [Related]
40. Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy.
Hull VL; Wang Y; McDonough J; Zhu M; Burns T; Al Ramel N; Dehghani A; Guo F; Pleasure D
Ann Clin Transl Neurol; 2024 Apr; 11(4):1059-1062. PubMed ID: 38282243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
